We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Brain Imaging Study of Nicotine Release in Cigarette Smokers

This study has been terminated.
(It was decided to use a different protocol with a different radioligand)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00254358
First Posted: November 16, 2005
Last Update Posted: July 4, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Herzog Hospital
Information provided by:
Hadassah Medical Organization
  Purpose
Tobacco Smoking is the most prevalent addiction in society today causing directly major health hazards and sharing morbidity with other psychiatric disorders. Nicotine binds to acetylcholine receptors and thus elevates DA release and inhibits DA transport. There are few studies using advanced brain imaging techniques to investigate how nicotine releases dopamine in humans. These studies utilized dopamine displacement paradigms with [11C] Raclopride binding to D2 receptor in Positron Emission Tomography (PET). There is evidence that smokers (particularly those who enjoyed smoking) showed decreased [11C] Raclopride binding in the caudate/nucleus accumbens and putamen after smoking cigarettes. These results also indicated that the effects of nicotine on dopaminergic neurotransmission are mediated by pleasure and craving. We propose to investigate the effects of smoking a cigarette ad lib on dopamine release by using dopamine competition paradigm with [I123] IBZM in SPECT. Secondly, we will test the hypothesis that dopamine deficiency is a major vulnerability factor for smoking. This may provide further evidence that dopamine deficiency in some smokers pre-disposes them to enjoy and desire smoking cigarettes more than others.

Condition
Nicotine Dependence

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: A Brain Imaging Study of Nicotine Release in Cigarette Smokers

Resource links provided by NLM:


Further study details as provided by Hadassah Medical Organization:

Enrollment: 0
Study Start Date: April 2007
Study Completion Date: April 2007
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
smokers in treatment with bupropion
Criteria

Inclusion Criteria:

  • Chronic smokers and healthy non-smokers.

Exclusion Criteria:

  • Pregnant and breast feeding women.
  • Age below 20.
  • Neurological disorders.
  • Others drugs.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00254358


Sponsors and Collaborators
Hadassah Medical Organization
Herzog Hospital
Investigators
Principal Investigator: Yodphat Krausz, MD Hadassah Medical Organization
  More Information

Responsible Party: Dr. Aviv Weinstein, Hadassah Medical Organization
ClinicalTrials.gov Identifier: NCT00254358     History of Changes
Other Study ID Numbers: 842902-HMO-CTIL
First Submitted: November 15, 2005
First Posted: November 16, 2005
Last Update Posted: July 4, 2008
Last Verified: June 2008

Keywords provided by Hadassah Medical Organization:
Nicotine
Dopamine
IBZM

Additional relevant MeSH terms:
Tobacco Use Disorder
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Nicotine
Ganglionic Stimulants
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action